Anthem Biosciences IPO Subscription started on Monday, July 14, and will close on July 16, 2025, as scheduled. The price band is set at ₹540 to ₹570 per share with a face value of ₹2.
Anthem Biosciences IPO Subscription Status
Anthem Biosciences IPO subscribed over 67.42x on its Last day till 05.00 PM on 16th July.
- Anthem Biosciences IPO subscription QIB investors portion is 192.80x times, while NII subscribers subscribed 44.70x times, and RII investors subscribed 5.98x times.
- The company has received bids for 2,81,49,30,794 shares against 4,17,50,321 shares on offer on the Last day.
- Anthem Biosciences IPO subscribed over 3.48x on day 2.
- Anthem Biosciences IPO subscribed over 0.77x on day 1.
About Anthem Biosciences IPO
Anthem Biosciences Limited, founded in 2006, is one of the growing innovation-driven and technology-focused Contract Research, Development and Manufacturing Organizations (“CRDMO”) with end-to-end operations covering drug discovery, development, and manufacturing. Anthem Biosciences is one of the few companies in India with integrated capabilities in New Chemical Entities (NCE) and New Biological Entities (NBE) throughout drug discovery, development, and commercial manufacturing.
Anthem Biosciences is a one-stop service provider engaged in serving a wide range of customers, including emerging biotech companies and large pharmaceutical firms around the world. The company is involved in the manufacturing of specialized fermentation-based APIs, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company has supplied to over 150 customers, from small biotech to large pharmaceutical companies, as of March 31, 2024. Currently, the company has a team of 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, and chemical engineers.
Anthem Biosciences IPO Company Financial Report
The company reported revenue of ₹1,930.29 crores in 2025 against ₹1,483.07 crores in 2024. The company reported a profit of ₹451.26 crores in 2025 against a profit of ₹367.31 crores in 2024.
Anthem Biosciences IPO GMP:
Anthem Biosciences IPO GMP was ₹157 as of Wednesday, July 16th, 2025. That indicates the IPO is trading at ₹727 with a ₹157 premium in the grey market against the issue price of ₹570.
